Drug Discovery

How to Triage Drug Targets Before Wet-Lab Validation

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

Use How to Triage Drug Targets Before Wet-Lab Validation to decide which targets should enter expensive experimental assessment first before the next expensive commitment. Build the comparison around public genetics, expression, pathway, essentiality, safety, tractability, and literature contradiction and ask what would overturn the preferred route; the earliest useful challenge is: test whether the shortlist survives independent datasets and alternate normalization choices. Stop at a provisional decision and preserve the remaining validation boundary.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which targets should enter expensive experimental assessment first

Why the problem is difficult

The article-specific identification challenge is whether the question “which targets should enter expensive experimental assessment first” can be resolved using public genetics, expression, pathway, essentiality, safety, tractability, and literature contradiction, rather than merely restated in new language.

A falsifier-first workflow

  • Define the decision precisely: which targets should enter expensive experimental assessment first.
  • Build a source and data ledger around public genetics, expression, pathway, essentiality, safety, tractability, and literature contradiction.
  • Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
  • Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
  • Run the lowest-cost discriminating challenge: test whether the shortlist survives independent datasets and alternate normalization choices.
  • Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

  • Decision impact: would the result materially change the choice about which targets should enter expensive experimental assessment first?
  • Evidence fit: does the available evidence—public genetics, expression, pathway, essentiality, safety, tractability, and literature contradiction—directly address the decision rather than merely correlate with it?
  • Discrimination: does the preferred route predict an outcome a credible alternative does not?
  • Robustness: does the ranking survive the challenge “test whether the shortlist survives independent datasets and alternate normalization choices”?
  • Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

public genetics, expression, pathway, essentiality, safety, tractability, and literature contradiction

Counterevidence

For this decision, a result from “test whether the shortlist survives independent datasets and alternate normalization choices” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which targets should enter expensive experimental assessment first or exposes why the available evidence cannot resolve it.

Fastest falsifier

test whether the shortlist survives independent datasets and alternate normalization choices

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “test whether the shortlist survives independent datasets and alternate normalization choices” without an independently supported alternative mechanism.

Evidence ceiling

Desk triage can deprioritize weak routes but cannot replace biological validation.

Sources and starting points

  • Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
  • ChEMBL — Curated bioactivity information for compounds, assays, and targets.
  • ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
  • PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
  • UniProt — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
  • AlphaFold Protein Structure Database — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

  1. Drug Target Prioritization: A Falsifier-First Framework
  2. Target Identification vs Target Validation in Drug Discovery
  3. What Counts as Evidence for Drug Target Validation?
  4. Map the Translational Gap Before Advancing a Drug Program

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “How to Triage Drug Targets Before Wet-Lab Validation” help make?
It supports a bounded decision about which targets should enter expensive experimental assessment first. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?
test whether the shortlist survives independent datasets and alternate normalization choices
Can computation validate the final scientific claim?
No. Desk triage can deprioritize weak routes but cannot replace biological validation. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?
Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.